- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rosen Law Firm Encourages Mereo BioPharma Investors to Secure Counsel Before Deadline
Investors who purchased Mereo ADSs between June 2023 and December 2025 may be eligible for compensation.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of American Depositary Shares (ADSs) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 of the important April 6, 2026 lead plaintiff deadline in a securities class action lawsuit against the company. The lawsuit alleges that Mereo provided investors with material misinformation about the expected results of its Phase 3 Orbit and COSMIC studies for its drug setrusumab in Osteogenesis Imperfecta (OI).
Why it matters
This case highlights the importance of transparency and accurate disclosures from publicly traded companies. Investors rely on this information to make informed decisions, and providing misleading statements can lead to significant losses. The Rosen Law Firm is encouraging affected Mereo investors to secure legal counsel to potentially recover damages.
The details
According to the lawsuit, Mereo's defendants provided investors with positive statements about setrusumab's ability to reduce annualized fracture rates in the Orbit and COSMIC studies, while concealing the fact that neither study hit their primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups. This allegedly caused investors to purchase Mereo's ADSs at artificially inflated prices, and when the true details emerged, investors suffered damages.
- The class period is from June 5, 2023 to December 26, 2025.
- The lead plaintiff deadline is April 6, 2026.
The players
Mereo BioPharma Group plc
A biopharmaceutical company focused on rare diseases.
Rosen Law Firm
A global investor rights law firm that is representing investors in this securities class action lawsuit against Mereo.
What they’re saying
“Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ('ADS') of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the 'Class Period'), of the important April 6, 2026 lead plaintiff deadline.”
— Rosen Law Firm (Globe Newswire)
What’s next
To join the Mereo class action, investors can go to the Rosen Law Firm's website or contact the firm for more information. The judge will decide on April 6, 2026 whether to allow a lead plaintiff to be appointed to represent the class.
The takeaway
This case underscores the need for public companies to provide accurate and transparent information to investors. Misleading statements can have serious consequences, and affected investors should consider seeking legal counsel to potentially recover damages.
